Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study

IMPORTANCE: The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Slovin, Susan, Clark, William, Carles, Joan, Krivoshik, Andrew, Park, Jung Wook, Wang, Fong, George, Daniel
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145657/
https://ncbi.nlm.nih.gov/pubmed/29222530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.3361
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados